ANTITUMOR-VEKTORKONSTRUKTE UND METHODEN

Patent europeic · EP0870018 · Stritgà

Inscripziun en il register

Numer da publicaziun
EP0870018
Numer da la dumonda
EP96932702
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
Stritgà
Scrittira da patent
Concedì
Annunzià
02-10-1996
Publitgà
14-10-1998
Concedì
27-03-2002
Stritgà
31-10-2006
Motiv
Taxa annuala betg pajada
Classas IPC
C12N 15/12 (2006.01)
C12N 15/54 (2006.01)
C12N 15/62 (2006.01)
C12N 15/63 (2006.01)
C12N 15/85 (2006.01)
C12N 5/10 (2006.01)
C07K 14/245 (2006.01)
C07K 14/435 (2006.01)
C07K 14/47 (2006.01)
C07K 14/82 (2006.01)
C12Q 1/68 (2006.01)
Prioritad
GB 9520079 02.10.1995
GB 9616685 08.08.1996
Dumonda PCT
PCT/GB1996/002416 02.10.1996
Publicaziun PCT
WO1997/012970 10.04.1997
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 15-06-2007

    Stritgà, taxa betg pajada

    Published in +pat+ No 11 in 2007

  2. 28-03-2002

    Concedì

    Published in PIDTJ No 6 in 2002

Partidas

Possessur

Cyclacel Limited

Marquis House, 67-68 Jermyn Street, London SW1Y 6NY, GB

Inventur

BALMAIN, Allan;c/o Onyx Pharmaceuticals

Richmond, CA 94806, US

ZHU, Jingde

Glasgow G61 1LN, GB

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.